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Abstract 
Antibiotic resistant pathogens are a major cause of nosocomial infections and exhibit 
an extraordinary ability to constantly adapt and acquire resistance determinants to 
overcome the effects of commonly prescribed antimicrobials. Glycopeptide resistant 
Enterococcus faecium, multidrug resistant Pseudomonas aeruginosa, Clostridium 
difficile and Escherichia coli are all pathogens of clinical interest, increasing in 
prevalence and causing large outbreaks of infection within hospitals. On the other 
hand, the emerging potential of vancomycin resistant Staphylococcus aureus 
(VRSA) and linezolid resistance in Gram-positive pathogens to follow suite provides 
a serious concern for the future treatment of hospital-acquired infections.  
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Introduction 
Antibiotic resistant bacteria are a major cause of nosocomial infections and are 
associated with increasing rates of mortality among hospitalised patients (Rossolini 
et al., 2010). The ability of these microorganisms to adapt and overcome the effects 
of therapeutic drugs provides an ever changing clinical battle. Of particular concern 
is the spectrum of antibiotic resistance exhibited by certain bacteria as new 
antimicrobials cannot be synthesised or discovered quickly enough. The resistant 
bacteria of current clinical interest are Staphylococcus aureus, Enterococcus 
faecium, Clostridium difficile, Pseudomonas aeruginosa and Escherichia coli. These 
pathogens are able to evade the effects of antibiotics via a multitude of mechanisms 
compromising the effective treatment of infections (Table 1).  
The hospital environment provides great selective antimicrobial pressure and a 
suitable area for dissemination of resistance determinants; the use of antibiotics and 
the presence of sensitive microorganisms allow the acquisition and transfer of 
resistance genes and thus the emergence of highly pathogenic bacteria (French, 
2010). The shift from sensitive to resistant bacteria populations is considered as an 
inevitable evolutionary response due to the extensive and concentrated use of 
antibiotics, making the future of successful treatment indeterminate. This article aims 
to review the current literature on the prevalence and mechanisms of antibiotic 
resistant nosocomial pathogens and consider the impact of this on the treatment of 
infections caused by such bacteria.  
Table 1: Nosocomial pathogens, resistance phenotype and mechanisms (adapted from 
Rice, 2009; Rossolini et al., 2010) 
 
Species Resistance Phenotype Mechanism(s) 
Staphylococcus aureus Methicillin 
 
Penicillin 
Oxacillin 
Clindamycin 
Vancomycin 
Altered penicillin-binding proteins 
(PBPs) 
β-lactamase 
Low-affinity PBP 
Constitutive erm expression 
Mechanism unclear 
Enterococcus faecium  Ampicillin 
Vancomycin 
Linezolid 
Daptomycin 
Low affinity PBPs 
Altered peptidoglycan precursor 
Mutant ribosomal RNA genes 
Mechanism unclear 
Clostridium difficile Rifamycins 
 
Macrolides & 
Clindamycin 
Fluoroquinolones 
Mutations in rpoB gene (decrease 
affinity of RNA target) 
Ribosomal target methylation by Erm 
expression 
Mutant DNA gyrase subunit 
Pseudomonas aeruginosa  Carbapenems 
 
Aminoglycosides 
Fluoroquinolones 
 
Penicillins 
Metallo-β-lactamases 
AmpC/porin reduction combinations 
Modifying enzymes 
Mutant topoisomerases 
Efflux pumps  
β-lactamases 
Escherichia coli Penicillins 
Fluoroquinolones 
Aminoglycosides 
β-lactamases 
Efflux pump 
Aceyltransferases 
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Vancomycin Resistant Staphylococcus aureus 
Staphylococcus aureus is undoubtedly the most notorious and prevalent Gram-
positive nosocomial pathogen found in clinical samples, being a leading cause of 
both skin structure infections and blood stream infections (EARRS, 2010). The ability 
of this microorganism to respond to its environment and adapt accordingly has 
enabled it to become resistant to an array of antimicrobials, thus providing a major 
resistance challenge within the health-care setting.  Vancomycin, a glycopeptide 
antibiotic, was first used clinically in 1958; however, its use has dramatically 
increased in the last thirty years as an effective treatment of severe methicillin 
resistant S. aureus (MRSA) infections (Srinivason et al., 2002). For this reason, the 
emergence of vancomycin intermediate S. aureus (VISA) and vancomycin resistant 
S. aureus (VRSA) strains is incredibly alarming.  
VISA was first displayed clinically in Japan in 1996, and although relatively 
uncommon the potential clinical challenge it poses should not be underestimated 
(Hiramatsu et al. 1997). This phenotype exhibits a thickened and poorly cross-linked 
peptidoglycan layer, able to sequester vancomycin. Cui et al. (2006) identified that 
the altered structure of the peptidoglycan has an increased number of D-ala-D-ala 
targets able to bind to the antibiotic within the outer extremities of the cell wall, thus 
sequestering it. However, Rossolini et al. (2010) emphasise the importance of the 
increased thickness of the peptidogylcan in preventing vancomycin from accessing 
and binding to the D-ala-D-ala targets. On the other hand, Periera et al. (2007) 
highlighted the decrease in the rate of diffusion of vancomycin to its target as a key 
consequence of the thickened cell wall.  Although not in agreement on the exact 
mechanism, these studies express the vital role of the modified peptidoglycan in 
preventing vancomycin from reaching the cytoplasmic membrane where it can exert 
its bactericidal effect. They also present the possibility that resistance and reduced 
susceptibility to vancomycin may indeed be multifactorial.  
VISA are mediated by chromosomal mutations; gradual mutations within sensitive 
strains of S. aureus involving such loci as vraSR and graSR lead to heterogenous 
VISA (hVISA), which in turn develop subpopulations of homogenous VISA (Howden 
et al., 2010). This is regulated by a two component signal-transduction system (Van 
RS in the case of vancomycin resistance). VanRS is activated in the presence of 
vancomycin, thus activating the specific loci (vraSR and graSR) and ultimately 
stimulating a defence mechanism (Neoh et al., 2008; Depardieu et al, 2007). 
Although beneficial, these multiple genetic alterations are associated with high 
fitness costs. Slower growth, decreased expression of virulence factors and reduced 
stability has been exhibited by VISA in vancomycin free medium (Majcherczyk et al., 
2008; McAleese et al., 2006). It can be proposed that these biological fitness issues 
are the reason for the current low prevalence of VISA in hospitals.  
More recently, and of greater concern is the emergence of high-level VRSA via the 
acquisition of van gene complexes from enterococcus species. Since 2002 eleven 
clinical VRSA isolates possessing the vanA operon have been reported (French, 
2010). The vanA operon is carried by the transposon Tn1546 and can be transferred 
to S. aureus by one or two genetic events. The initial step is the transfer of Tn1546 
from enterococci to S. aureus by conjugation. As some enterococcal plasmids are 
less efficient at replication and unstable in S. aureus a further step is required; 
transposition of Tn1546 from the donor plasmid to a plasmid or chromosome located 
in S. aureus results in the illegitimate recombination of Tn1546 and the loss of the 
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enterococcal plasmid (Zhu et al., 2008). It is this operon that mediates the synthesis 
of altered peptidoglycan precursors (D-ala-D-lactate or D-ala-D-serine 
depsipeptides) and the production of D,D-peptidases that hydrolyse any D-ala-D-ala 
terminating peptidoglycan precursors, thus preventing vancomycin from reaching its 
target and ultimately conferring glycopeptide resistance to S. aureus (Perichon et al., 
2009). Although Rossolini et al., (2010) argues VRSA is not expected to play a major 
role as a nosocomial pathogen in the near future, Perichon et al., (2009) states the 
acquisition of vancomycin resistance by S. aureus is a ‘major public health problem’. 
Indeed the prevalence of MRSA and enterococci, along with the increased use of 
vancomycin in hospitals provides great potential for VRSA to consistently form and 
disperse within a clinical setting. 
The continued ability of S. aureus to become resistant to virtually all antibiotics is 
evident in the development of linezolid resistance. Linezolid is the new ‘last line drug’ 
for the treatment of S. aureus infections, however in 2008 a clinical outbreak of 
linezolid resistant S. aureus (LRSA) was observed in an intensive care unit (Fereres 
et al., 2010). This outbreak was the first to be mediated by the cfr gene, (confers 
chloramphenicol-florfenicol resistance) which is a transferable mechanism and 
therefore of considerable concern (especially as linezolid is fully synthetic). The cfr 
gene encodes a methyltransferase that catalyses the methylation of A2503 in the 
23S rRNA gene of the large ribosomal subunit, thus altering the antibiotics target and 
preventing it from inhibition (Morales et al. 2010). An alternative mechanism of LRSA 
is associated with chromosomal point mutations in the drug’s target site (V region of 
23S rRNA) induced by prolonged exposure to the antibiotic, although this remains 
uncommon it does identify the generation of de novo resistance (Besier et al., 2008).  
Glycopeptide resistance in Enterococci 
Enterococci are Gram-positive bacteria that typically colonise the gastrointestinal 
tract of humans and animals. Once thought to be harmless commensals, enterococci 
have emerged as a key nosocomial pathogen causing urinary tract infections, 
bloodstream and surgical site infections in hospitalised patients (Rossolini et al., 
2010; Top et al., 2008). Intrinsically resistant to a number of antibiotics and able to 
easily acquire resistant plasmids (Table 2), Enterococcus faecalis and E. faecium 
are the two species of particular clinical interest. 
Vancomycin resistant enterococci (VRE) were first identified in Europe in 1986 and 
the prevalence of infections have been increasing since 2000 (Uttley et al., 1988; 
EARSS, 2010). The majority of clinical infections (80-90%) were caused by E. 
faecalis (Low et al., 2001). However over the past few years E. faecium has 
emerged as a significant multi-resistant nosocomial pathogen due to its ability to 
adapt and exploit the hospital environment, and readily exchange antimicrobial 
resistant genes (Top et al., 2008). Indeed Willems et al., (2005) identified that most 
of the hospital-acquired VRE infections are caused by a single genetic lineage of E. 
faecium, clonal complex 17 (CC17). CC17 is a prime example of how stress inducing 
factors (antimicrobial use within hospitals) can favour the selection of a 
subpopulation exhibiting enhanced virulence and ability to spread due to the 
acquisition of antimicrobial resistance.  The resilience of enterococci to survive 
rigorous cleaning and sterilisation in a clinical setting has also undoubtedly 
contributed to its establishment as one of the most formidable nosocomial pathogens 
(Kearns et al., 1995; Hayden, 2000). It has been suggested that the emergence of 
VRE was due, directly, to an increased use of vancomycin in the USA, thus 
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highlighting the adverse consequence of using antibiotics (Bonten et al., 2001). 
However Witte (2004) draws attention to the central role of E. faecium in acquiring, 
conserving and transferring antibiotic resistance genes.  
Table 2: Antibiotic resistance of enterococci (adapted from Top et al. 2008) 
 
Vancomycin resistance is mediated by the acquisition of van gene clusters which 
code for the production of modified peptidoglycan. The D-ala-D-ala dipeptide is 
replaced by a depsipeptide composed of D-alanyl-D-lactate or D-alanyl-D-serine, 
thus lowering the affinity of the glycopeptide-binding target (Reynolds and Courvalin, 
2005; Boyd et al., 2008). Numerous van gene clusters have been identified in 
enterococci (vanA to vanL), with an eighth recently described by Xu et al., (2010); 
vanM is considered to confer vancomycin resistance via a similar mechanism to that 
of vanA, (inducible synthesis of D-alanyl-D-lactate ligase and able to be transferred 
by conjugation), however identification of this van cluster remains uncommon at 
present. VanA and vanB are the most prevalent van gene clusters in clinical isolates 
and are located on transposons; Tn1546 and Tn1549 respectively (Rossolini et al., 
2010). As Tn1546 does not encode any conjugative functions, but Tn1549 does, it 
can be inferred that dissemination of vancomycin resistance is due to both the clonal 
expansion of resistant strains and the horizontal gene transfer between strains (Top 
et al., 2008). These mobile genetic elements have played a huge part in the 
development of highly hospital-adapted strains and are now moving glycopeptide 
 Antibiotic  Species Resistance Mechanism  
Intrinsic 
resistance  
β-Lactams 
   Penicillins (low level) 
   Carbepenems (moderate 
level) 
   Cephalosporins (high 
level) 
 
Aminoglycosides (low level) 
Aminoglycosides (moderate 
level) 
Lincosamides & 
streptogramins A 
 
Glycopeptides (low level) 
All enterococci 
 
 
 
 
 
 
All enterococci 
E. faecium  
 
E. faecalis, E. avium,  
E. gallinarum,  
E. casseliflavus 
E. gallinarum,  
E. casseliflavus 
Low affinity PBPs 
 
 
 
 
 
 
Inefficient uptake 
Production of chromosomal 
AAC(6’)li enzyme 
Putative efflux  
 
 
Production of D-Ala-D-Ser 
peptidoglycan precursors 
Acquired 
resistance 
Ampicillin (high level) 
 
Aminoglycosides (high 
level) 
 
Macrolides 
Chloramphenicol 
Tetracycline 
Quinolones 
 
Glycopeptides (high level) 
 
Oxazolidinones 
E. faecium, E. hirae  
 E. faecalis 
E. faecalis, E. faecium, 
 E. gallinarum,  
E. casseliflavus 
Most enterococci 
E. faecium, E. faecalis 
E. faecium, E. faecalis 
E. faecium, E. faecalis 
 
E. faecium, E. faecalis 
 
E. faecium 
Overproduction or alterations of 
PBP5 Β-lactamase (rare) 
Aminoglycosides modifying 
enzymes e.g. AAC (6’)-APH (2”) 
 
Ribosomal methylation 
CAT encoding enzymes  
Modification of ribosome protein 
Alterations in DNA gyrase and 
Topoisomerase IV 
Peptidoglycan precursor 
modification 
Mutation in 23S rRNA gene 
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resistance to other bacterial species such as S. aureus (as previously 
described)which causes great concern when vancomycin is referred to as a ‘last line’ 
drug.  
Linezolid is a key therapy for the treatment of VRE, and it was thought that 
development of resistance would be a rare event. However, in recent years linezolid 
resistance has been exhibited both in vitro and in clinical isolates of enterococci 
(Gomez-Gil et al., 2009; Gonzales et al., 2001). Similarly to S. aureus, the main 
mechanism of resistance is attributed to the single point mutation G2576U within the 
23S rRNA gene, which alters the target of the drug (Scheetz et al., 2006). 
Furthermore, a recent study by Long et al. (2010) identified that double 23S rRNA 
mutations have a remarkable synergistic effect on linezolid resistance, in comparison 
to the effects of the corresponding single mutations.  Although surveillance 
programmes stress it is still uncommon in hospitals, research has identified the 
formation of linezolid-resistant subpopulations suggesting the continued emergence 
of this phenotype upon increased use of linezolid (Farrell et al., 2009; Allen et al., 
2009).  
 Multidrug Resistant Clostridium difficile 
Clostridium difficile, a Gram- positive bacterial bacillus, differs from other nosocomial 
pathogens in that the emergence and prevalence of resistant strains is not directly 
linked to the treatment of C. difficile infection (CDI). Resistance to erythromycin, 
clindamycin and fluoroquinolones is exhibited among most pathogenic strains of C. 
difficile and is considered to have arisen due to their use in the treatment of other 
bacterial infections (Huang et al., 2009). The use of broad-spectrum antibiotics alters 
the microflora of the intestinal gut (where C. difficile colonise) thus allowing 
pathogenic strains of C. difficile to proliferate and CDI to occur. Many consider 
antibiotic usage and poor hygiene within a clinical setting as key underlying factors of 
CDI outbreaks (French, 2010).   
Large outbreaks of CDI have been found to be caused by so-called ‘hypervirulent’ 
strains, such as polymerase chain reaction (PCR) ribotype 001, 027 and 106. PCR 
ribotype 027 is considered as the most common in clinical isolates; indeed studies 
have shown these strains to be associated with an increased severity of infection 
and high mortality rate (Coia, 2009). Features of all PCR ribotypes include deletions 
in the tcdC regulatory locus allowing the hyperproduction of toxins A and B, and 
resistance to an array of antibiotics (particularly fluoroquinolones) (McDonald et al., 
2005). The resistant mechanisms exploited by C. difficile vary depending on the 
agent used; ribosomal methylation mediated by erm genes confers high level 
resistance to erythromycin and clindamycin, whereas fluoroquinolone resistance is 
caused by amino acid substitutions in the quinolone-resistant determining region 
(QRDR) of target enzymes (typically GyrA or GyrB subunits). In addition, an 
increased efflux of the drug has been identified to confer fluoroquinolone resistance 
(Huang et al., 2009).   
Vancomycin and metronidazole are the antibiotics of choice to treat CDI. Although 
resistance to these agents remains uncommon, a decreased susceptibility has been 
reported in several studies. Pelaez et al., (2008) illustrated that metronidazole 
resistance is inducible and Baines et al., (2008) described an increased minimum 
inhibitory concentration (MIC) for metronidazole for PCR ribotype 001 in the UK. 
Although the exact mechanisms remain to be elucidated, the reduced uptake of 
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metronidazole and reduced nitroreductase activity have been suggested as possible 
methods. Similarly, Mutlu et al., (2007) demonstrated an increase in the number of 
isolates displaying an increased MIC for vancomycin. Again, the mechanism of 
resistance remains unclear, however the acquisition of van gene clusters from 
enterococci could be possible as Jasni et al., (2010) demonstrated that the transfer 
of resistance genes between the two bacteria can occur.  
Multidrug Resistant Pseudomonas aeruginosa 
Pseudomonas aeruginosa, a Gram-negative rod shaped bacterium, is a major cause 
of nosocomial respiratory, urinary and bloodstream infections in 
immunocompromised patients, especially those suffering with cystic fibrosis. 
Antibiotic resistance is a key factor in the pathogenicity of this microorganism, as 
infection caused by resistant strains is associated with a threefold increased rate of 
mortality (Mesaros et al., 2007). P. aeruginosa provides a particularly problematic 
clinical challenge as not only is it intrinsically resistant to an array of antibiotics, its 
high versatility and adaptive capacity allows it to acquire resistance traits as well. 
Furthermore, its ability to form biofilms on medical equipment (catheters and 
prosthetic joints) and the lungs of cystic fibrosis patients makes effective treatment 
rather complicated, and sometimes near impossible.  
Planktonic P. aeruginosa, as with other nosocomial pathogens, display a multitude of 
mechanisms to overcome the bactericidal and bacteriostatic effects of antibiotics 
(Table 3).  
Table 3: Mechanisms of resistance exhibited by Pseudomonas aeruginosa (adapted from 
Mesaros et al. 2007) 
Antibiotic Mechanism of resistance 
Penicillins and cephalosporins Active efflux 
Cephalosporinase overexpression 
Restricted-spectrum penicillinases 
Extended-spectrum oxacillinases  
Extended-spectrum β-lactamases 
Metallo- β-lactamases 
Aztreonam Active efflux 
Cephalosporinase overexpression 
Restricted-spectrum penicillinases 
Extended-spectrum oxacillinases  
Extended-spectrum β-lactamases 
Imipenem Metallo- β-lactamases 
Alterations of OprD porin (reduced outer membrane 
permeability) 
Meropenem Active efflux 
Metallo- β-lactamases 
Alterations of OprD porin (reduced outer membrane 
permeability) 
Aminoglycosides Active efflux 
Aminoglycoside-modifying enzymes 
Ribosomal methylation 
Fluoroquinolones  Active efflux 
Mutations in topisomerases 
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The production of β-lactamases, efflux pumps and a low permeability of the outer 
membrane are all intrinsic to P. aeruginosa, whilst the modification of targets, 
expression of porins and expression of inactivating enzymes for aminoglycosides are 
all mechanisms that are acquired from other bacteria (Riou et al., 2010). Efflux 
pumps are a widespread component of resistant strains and work alongside the low 
permeability of the outer membrane to form resistance to aminoglycosides, β-
lactams, macrolides, fluoroquinolones and tetracycline (Schweizer, 2003; Poole et 
al., 2001). Although found to confer low levels of resistance, Niga et al., (2005) 
demonstrated that the overexpression of efflux pumps (induced in response to 
antimicrobial pressure) lowers the intra-bacterial antibiotic concentration and thus 
favours the emergence of target mutations in DNA gyrase (GyrA), conferring high 
level fluoroquinolone resistance. Such other target mutations as the methylation of 
16S rRNA confers resistance to aminoglycosides and is thought to have been 
acquired from Gram-positive bacteria (Liou et al., 2006). Recently, Su et al., (2010) 
demonstrated that the development of fluoroquinolone resistance determinants, such 
as efflux pumps, is a multifaceted process and that pre-existing cellular pathways act 
in support of inducible genetic mutations, working together to produce resistance. 
This information may be applied to the development of novel strategies to prevent 
the emergence of fluoroquinolone resistance in other bacteria.  
P. aeruginosa present in biofilms can be up to a thousand times more resistant, 
exhibiting an increased tolerance to antimicrobials as well as withstanding the effects 
of the body’s immune system. Indeed chronic lung infections in cystic fibrosis 
patients are caused by biofilm-growing mucoid strains and the development of 
resistance to all available antibiotics has been reported (Hoiby et al., 2010). Typical 
resistance mechanisms such as those previously mentioned do contribute to the 
overall survival of biofilms, however the increased mutation frequency, altered 
growth rate, quorum sensing and persister variants are considered to be integral to 
the increased resistance (Harmsen et al., 2010).  Although a rather obvious 
resistance mechanism would be the barrier provided by the exopolysaccharide 
matrix many reports have provided conflicting results; Vrany et al., (1997) 
demonstrated that the penetration of ciprofloxacin and levofloxacin through a P. 
aeruginosa biofilm was not significantly delayed, whilst Suci et al., (1994) indicated 
that the diffusion of ciprofloxacin was significantly delayed in the presence of a 
biofilm. With this in mind, Walters et al. (2003) concluded that the delayed 
penetration of antimicrobials was not a significant factor in the increased resistance 
of biofilms, but suggested that low growth rate and oxygen limitation were more 
accountable. Indeed studies by Folsom et al., (2010) and King et al., (2010) support 
this hypothesis. The elevated antimicrobial resistance of biofilms is widely 
considered to be multifactorial, with many studies emphasising the importance of 
altered phenotypes (persister cells in particular are key to the survival of populations) 
and horizontal gene transfer (allows acquisition of resistance genes and the 
development of multi-drug resistance in an entire population) (Molin et al., 2003; De 
Groote et al., 2009).  
Multidrug resistant Escherichia coli 
Escherichia coli is not traditionally associated with nosocomial infections, however 
due to the acquisition of resistance determinants, it has emerged as the leading 
Gram-negative pathogen responsible for bloodstream and urinary tract infections. In 
2008 E. coli exhibited a Europe-wide increase of resistance to fluoroquinolones, third 
generation cephalosporins and aminoglycosides. Of more importance, an increased 
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frequency of multidrug resistance was observed, identifying it as a major threat to 
public health (EARRS, 2010).  
CTX-M extended spectrum β-lactamase (ESBL) producing E. coli have rapidly 
emerged over the past decade and are largely associated with a nosocomial setting 
(Rodriguez-Bano et al., 2006). CTX-M enzymes render E. coli resistant to a variety 
of β-lactams, specifically cefotaxime, and are transferred via plasmids that can also 
include resistance genes to numerous unrelated classes of antibiotics (Canton et al., 
2006).  Recent studies have demonstrated the acquisition of multiple antibiotic 
plasmid genes by CTX-M producing E. coli; Jiang et al., (2008) and Cattoir et al., 
(2008) reported the acquisition of quinolone resistance genes (qepA, qnr, and 
aac(6’)-Ib-cr) whereas Baudry et al., (2009) reported the presence of the 
aminoglycoside resistance gene aac(3’)-II. Whilst aac(6’)-Ib-cr and aac(3’)-II both 
code for aceyltransferases, qepA codes for a quinolone efflux pump and qnr codes 
for Qnr peptides (pentapeptide repeat proteins) which protect DNA gyrase and 
topisomerase IV from inhibition; this highlights the variability of resistance 
mechanisms exploited by E. coli (Jiang et al., 2008; Baudry et al., 2009). The 
accumulation of the aforementioned resistance genes has given rise to multidrug 
resistant CTX-M producing E. coli thus limiting therapeutic options. Furthermore, the 
emergence of carbapenem (so-called drug of ‘last resort’) resistance among CTX-M 
producing E. coli is also a cause for serious concern. The newly identified New Delhi 
metallo- β-lactamase (NDM-1) confers resistance to all suitable antibiotics for 
infections caused by CTX-M producing E. coli, except colisitin and tigecycline 
(Kumarasamy et al., 2010). Moreover, there is increasing evidence of its ability to 
spread; isolates displaying this carbapenemase have been found in the UK, India, 
Pakistan and Australia (Kumarasamy et al., 2010; Poirel et al., 2010). These findings 
confirm the ability of resistance determinants to spread rapidly and be co-selected 
for in a hospital environment, adding further to the clinical issue of antibiotic 
resistance.   
Conclusion  
The issue of hospital-acquired infections caused by antibiotic resistant bacteria is 
one that should, by under no means, be underestimated. The ability of such 
notorious pathogens as S. aureus and E. faecium to evade the effects of newly 
synthesised, as well as traditional antimicrobials, is incredibly detrimental to public 
health. Furthermore, the development of multidrug resistant C. difficile, P. 
aeruginosa and E. coli leaves very limited treatment options. Research efforts to 
elucidate the mechanisms of resistance have provided key insights, however further 
expansion of this is required to gain a comprehensive understanding, thus allowing 
the development of new, alternative treatments and perhaps more accurately predict 
the evolution of resistance. Current outbreaks of nosocomial infections caused by 
resistant bacteria should drive efforts to prevent such emerging outbreaks as VRSA 
and linezolid-resistant enterococci from resulting in a global problem. The key, and 
first, control strategy to deploy would perhaps be the strict administration of 
antibiotics in a bid to reduce the current selection pressure found in hospitals and 
maintain antimicrobial susceptibility at an appropriate level.  
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